机构:[1]State Key Laboratory of Genetic Engineering, Zhongshan Hospital, Fudan University, and School of Life Sciences, Fudan University, Shanghai, China[2]Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China[3]Department of Neurosurgery, Tangdu hospital, the Fourth Military Medical University, Xi’an, China[4]Shanghai Ji Ai Genetics and IVF Institute, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China[5]State Key Laboratory of Organ Failure Research, Guangdong Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, GuangZhou, China[6]Translational Genomics Research Institute (TGen), Phoenix, AZ[7]Department of Epidemiology, Center for Global Health, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center For Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China[8]Department of Neurosurgery, Shanghai Institute of Neurosurgery, Changzheng Hospital, Second Military Medical University, Shanghai, China[9]Department of Neuroscience, Tianjin Huanhu Hospital, Tianjin, China[10]Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, IL[11]Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China[12]Department of Medicine, The University of Chicago, Chicago, IL[13]Department of Neurosurgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China[14]Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China研究所北京市神经外科研究所首都医科大学附属天坛医院
Glioma is the most common malignant primary brain tumors with poor prognosis. Genome wide association studies (GWAS) of glioma in populations with Western European ancestry were completed in the US and UK. However, our previous results strongly suggest the genetic heterogeneity could be important in glioma risk. To systematically investigate glioma risk-associated variants in Chinese population, we performed a multistage GWAS of glioma in the Han Chinese population, with a total of 3,097 glioma cases and 4,362 controls. In addition to confirming two associations reported in other ancestry groups, this study identified one new risk-associated locus for glioma on chromosome 12p11.23 (rs10842893, p(meta) = 2.33x10-12, STK38L) as well as a promising association at 15q15-21.1 (rs4774756, p(meta) = 6.12x10-8, RAB27A) in 3,097 glioma cases and 4,362 controls. Our findings demonstrate two novel association between the glioma risk region marked by variant rs10842893 and rs4774756) and glioma risk. These findings may advance the understanding of genetic susceptibility to glioma.
基金:
the National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81071739, 81772657, 81372706, 81372235]
第一作者机构:[1]State Key Laboratory of Genetic Engineering, Zhongshan Hospital, Fudan University, and School of Life Sciences, Fudan University, Shanghai, China
共同第一作者:
通讯作者:
通讯机构:[1]State Key Laboratory of Genetic Engineering, Zhongshan Hospital, Fudan University, and School of Life Sciences, Fudan University, Shanghai, China[*1]State Key Laboratory of Genetic Engineering, Zhongshan Hospital, Fudan University, and School of Life Sciences, Fudan University, Shanghai, China
推荐引用方式(GB/T 7714):
Hongyan Chen,Gong Chen,Gang Li,et al.Two novel genetic variants in the STK38L and RAB27A genes are associated with glioma susceptibility[J].INTERNATIONAL JOURNAL OF CANCER.2019,145(9):2372-2382.doi:10.1002/ijc.32179.
APA:
Hongyan Chen,Gong Chen,Gang Li,Shuo Zhang,Haitao Chen...&Daru Lu.(2019).Two novel genetic variants in the STK38L and RAB27A genes are associated with glioma susceptibility.INTERNATIONAL JOURNAL OF CANCER,145,(9)
MLA:
Hongyan Chen,et al."Two novel genetic variants in the STK38L and RAB27A genes are associated with glioma susceptibility".INTERNATIONAL JOURNAL OF CANCER 145..9(2019):2372-2382